Cantrixil is a drug candidate in development for treating advanced cancer. It consists of the active molecule TRX-E-002-1, a potent and selective third-generation benzopyran, encapsulated in cyclodextrin. Cantrixil targets the full spectrum of cancer cells, including chemotherapy-resistant tumor-initiating cells believed to be responsible for relapse.
In preclinical studies, Cantrixil has demonstrated strong physicochemical properties, an acceptable safety profile, and minimal off-target effects. New data from 2024–2025 show strong cytotoxicity at low doses, and clear positive effects in combination with other cancer drugs in several hematologic cancer cell lines. In animal models, Cantrixil has shown reduced tumor growth, improved survival, and good tolerability, supporting further development for upcoming studies.
Based on preclinical data and with the aim to maximize commercial potential, Vivesto is focusing Cantrixil’s development on hematologic cancers (blood cancers).
Patent protection
Cantrixil has strong patent protection in the granted substance patent. In addition, Vivesto is seeking further ways to strengthen the intellectual property rights for Cantrixil through use patents. Furthermore, certain uses may be protected as orphan drugs.
| Family name | Scope summary |
|---|---|
| Cantrixil substance | Cantrixil molecule and related substances |
| Cantrixil use | Use of Cantrixil for certain cancers |